Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCom.int.bk.regs Regulatory News (CBKD)

Share Price Information for Com.int.bk.regs (CBKD)

Share Price is delayed by 15 minutes
Get Live Data
2.58    -0.015 (-0.58%)
Bid:
2.585
Ask:
2.59
Spread: 0.005 (0.193%)
Market Cap: $8.51b
CBKD Live PriceLast checked at - London Stock Exchange

Intraday Com.int.bk.regs Share Chart

  • This share is an international stock.

3rd Quarter Results

3 Nov 2023 07:05

RNS Number : 2593S
Commercial Intnl Bank (Egypt) SAE
03 November 2023
Β 

Commercial International Bank (Egypt) S.A.E.

Separate Financial Statements

Β 

September 30, 2023

Β 

Β 

Β 

Condensed Separate Interim Statement of Financial Position as at September 30, 2023

Β 

Notes

Sep. 30, 2023

Β 

Dec. 31, 2022

EGP Thousands

Β 

EGP Thousands

Β 

Β 

Assets

Β 

Β 

Β 

Cash and balances at the central bank

8

59,818,535

Β 

47,384,574

Due from banks

9

276,244,051

Β 

133,766,196

Loans and advances to banks, net

11

-

Β 

2,978,197

Loans and advances to customers, net

12

222,326,692

Β 

192,621,288

Derivative financial instruments

1,647,485

Β 

1,939,961

Financial investments

Β 

Β 

Β 

- Financial Assets at Fair Value through OCI

13

188,243,712

Β 

202,916,225

- Financial Assets at Amortized cost

13

38,686,046

Β 

34,178,753

- Investments in associates and subsidiaries

14

694,633

Β 

1,074,250

Non current assets held for sale

27

159,828

Β 

-

Other assets

15

17,327,838

Β 

14,454,868

Deferred tax assets

1,137,342

Β 

24,240

Property and equipment

16

2,456,340

Β 

2,304,513

Total assets

Β 

808,742,502

Β 

633,643,065

Liabilities and equity

Β 

Β 

Β 

Liabilities

Β 

Β 

Β 

Due to banks

17

19,030,415

Β 

3,475,848

Due to customers

18

665,894,926

Β 

530,124,905

Derivative financial instruments

99,911

Β 

219,752

Current income tax liabilities

6,993,454

Β 

3,051,583

Other liabilities

19

15,475,422

Β 

11,549,472

Issued debt instruments

20

3,071,834

Β 

2,456,607

Other loans

10,387,714

Β 

7,978,975

Other provisions

21

10,510,696

Β 

7,065,292

Total liabilities

Β 

731,464,372

Β 

565,922,434

Equity

Β 

Β 

Β 

Issued and paid up capital

30,195,010

Β 

29,825,134

Reserves

23,549,307

Β 

19,502,716

Reserve for employee stock ownership plan (ESOP)

1,339,443

Β 

1,895,435

Retained earnings *

22,194,370

Β 

16,497,346

Total equity and net profit for the period / year

Β 

77,278,130

Β 

67,720,631

Total liabilities and equity

Β 

808,742,502

Β 

633,643,065

The accompanying notes are an integral part of these financial statements.

Β 

(Limited review report attached)

Β 

*

Including net profit for the current period

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Condensed Separate Interim Income Statement for the period ended September 30, 2023

Β 

Β 

Β 

Β 

Β 

Β 

Last 9 Months

Β 

Last 9 Months

Notes

Sep. 30, 2023

Β 

Sep. 30, 2022

EGP Thousands

Β 

EGP Thousands

Β 

Β 

Interest and similar income

72,741,395

Β 

38,761,627

Interest and similar expense

(35,154,201)

Β 

(17,050,977)

Net interest income

Β 

37,587,194

Β 

21,710,650

Β 

Β 

Fee and commission income

6,540,630

Β 

3,900,488

Fee and commission expense

(2,590,207)

Β 

(1,730,066)

Net fee and commission income

Β 

3,950,423

Β 

2,170,422

Β 

Β 

Dividend income

100,244

Β 

64,372

Net trading income

5

3,146,544

Β 

1,431,729

Profits (Losses) on financial investmentsΒ 

13.1

(1,256,233)

Β 

1,096,850

Administrative expenses

(6,304,022)

Β 

(5,024,897)

Other operating (expenses) income

6

(5,293,795)

Β 

(3,399,057)

Impairment release (charges) for credit losses

(1,248,897)

Β 

(262,606)

Profit before income tax

Β 

30,681,458

Β 

17,787,463

Β 

Β 

Income tax expense

25

(9,540,541)

Β 

(4,984,283)

Deferred tax assets (Liabilities)

25

591,159

Β 

(597,258)

Net profit for the period

Β 

21,732,076

Β 

12,205,922

Β 

Β 

Earnings per share

7

Β 

Β 

Basic

6.41

Β 

3.62

Diluted

6.34

Β 

3.58

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Condensed Separate Interim statement of Comprehensive Income for the period ended September 30, 2023

Β 

Last 9 Months

Β 

Last 9 Months

Sep. 30, 2023

Β 

Sep. 30, 2022

EGP Thousands

Β 

EGP Thousands

Β 

Β 

Net profit for the period

21,732,076

Β 

12,205,922

Β 

Β 

Change in fair value of Financial invesments measured at fair value through comprehensive income after tax

(9,611,703)

Β 

(13,128,801)

Transferred to RE from financial assets at fair value through comprehensive income

(95,308)

Β 

(4,128)

Effect of ECL in fair value of debt instruments measured at fair value through comprehensive income

197,888

Β 

233,717

Total comprehensive income for the period

Β 

12,222,953

Β 

(693,290)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Condensed Separate Interim Cash flows for the period ended September 30 2023

Β 

Β 

Notes

Sep. 30, 2023

Β 

Sep. 30, 2022

EGP Thousands

Β 

EGP Thousands

Β 

Β 

Cash flow from operating activities

Β 

Β 

Β 

Profit before income tax

30,681,458

Β 

17,787,463

Adjustments to reconcile profits to net cash provided by operating activities

Β 

Β 

Β 

Fixed assets depreciation

16

636,285

654,220

Impairment (Released) charge for credit losses (Loans and advances to customers and banks)

1,088,174

(16,255)

Other provisions charged ( Released )

21

2,350,347

1,803,863

Impairment (Released) charge for credit losses (due from banks)

(49,019)

849

Impairment (Released) charge for credit losses (financial investments)

209,742

278,012

Impairment (Released) charge for other assets

14,347

(277,768)

Exchange revaluation differences for financial assets at fair value through OCI and AC

(5,409,592)

(3,745,045)

Utilization of other provisions

21

(1,608)

(1,857)

Other provisions no longer used

21

-

(101)

Exchange revaluation differences of other provisions

21

1,096,665

333,425

profits from selling property and equipment

(194)

(2,192)

profits from selling financial investments at fair value through OCI

13.1

(149,012)

(1,096,850)

Losses (Profits) from selling investments in associates

13.1

(7,466)

-

Shares based payments

608,250

579,653

Impairment (Released) charges of investments in associates and subsidiaries

13.1

1,412,711

-

Operating profits before changes in operating assets and liabilities

Β 

32,481,088

Β 

16,297,417

Β 

Β 

Net decrease / increase in assets and liabilities

Β 

Β 

Β 

Due from banks

5,142,259

845,633

Financial assets at fair value through P&L

-

240,987

Derivative financial instruments

172,635

(947,116)

Loans and advances to banks and customers

11 - 12

(27,805,660)

(33,520,003)

Other assets

(2,507,984)

1,242,254

Due to banks

17

15,554,567

841,125

Due to customers

18

135,770,021

91,483,674

Current income tax obligations paid

(2,547,087)

(2,305,911)

Other liabilities

874,366

(310,752)

Net cash generated from (used in) operating activities

Β 

157,134,205

Β 

73,867,308

Β 

Β 

Cash flow from investing activities

Β 

Β 

Β 

Proceeds from investments in associates.

2,119

-

Payments for investment in subsidiaries

(1,216,022)

(59,900)

Payment for purchases of property, equipment and branches construction

(1,162,819)

(542,743)

Proceeds from selling property and equipment

194

2,192

Proceeds from redemption of financial assets at amortized cost

5,278,030

6,569,803

Payment for purchases of financial assets at amortized cost

(9,178,811)

(18,239,332)

Payment for purchases of financial assets at fair value through OCI

(65,109,765)

(114,918,927)

Proceeds from selling financial assets at fair value through OCI

76,347,190

73,463,225

Net cash generated from (used in) investing activities

Β 

4,960,116

Β 

(53,725,682)

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Condensed Separate Interim Cash flows for the period ended September 30, 2023 (Cont.)

Β 

Β 

Sep. 30, 2023

Β 

Sep. 30, 2022

EGP Thousands

Β 

EGP Thousands

Β 

Β 

Cash flow from financing activities

Β 

Β 

Β 

Other loans

2,408,739

1,116,344

Dividends paid

(3,738,888)

(4,410,322)

Issued debt instruments

615,227

382,977

Capital increase

369,876

122,716

Net cash generated from (used in) financing activities

Β 

(345,046)

Β 

(2,788,285)

Β 

Β 

Β 

Β 

Net (decrease) increase in cash and cash equivalent during the period

161,749,275

17,353,341

Beginning balance of cash and cash equivalent

92,895,143

60,891,899

Cash and cash equivalent at the end of the period

Β 

254,644,418

Β 

78,245,240

Β 

Β 

Cash and cash equivalent comprise:

Β 

Β 

Β 

Cash and balances at the central bank

59,818,535

43,776,754

Due from banks

276,244,266

90,419,482

Treasury bills

10

71,507,826

Β 

87,119,766

Obligatory reserve balance with CBE

(52,853,882)

Β 

(38,022,832)

Due from banks with maturity more than three months

(29,659,932)

(22,949,758)

Treasury bills with maturity more than three months

(70,412,395)

(82,098,172)

Total cash and cash equivalent

Β 

254,644,418

Β 

78,245,240

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Condensed Separate Interim statement of changes in shareholders' equity

Β 

Sep. 30, 2022

Issued and paid up capital

Legal reserve

General reserve

General risk reserve

Capital reserve

Reserve for financial assets at fair value through OCI

Banking risks reserve

Retained earnings

Reserve for employee stock ownership plan

Total

Β 

Beginning Balance at 1 Januray 2022

19,702,418

3,293,074

28,260,532

1,549,445

16,000

639,231

9,141

13,783,935

1,674,392

68,928,168

Capital increase

10,122,716

-

(10,000,000)

-

-

-

-

-

-

122,716

Transferred to reserves

-

670,872

8,836,326

-

2,947

-

-

(9,007,223)

(502,922)

-

Dividend paid

-

-

-

-

-

-

-

(4,410,322)

-

(4,410,322)

Net profit for the period

-

-

-

-

-

-

-

12,205,922

-

12,205,922

Transferred to RE from financial assets at fair value through OCI

-

-

-

-

-

(4,128)

-

4,128

-

-

Net unrealised gain/(loss) on financial assets at fair value through OCI after tax

-

-

-

-

-

(13,128,801)

-

-

-

(13,128,801)

Transferred (from) to bank risk reserve

-

-

-

-

-

-

2,840

(2,840)

-

-

Effect of ECL in fair value of debt instruments measured at fair value through OCI

-

-

-

-

-

233,717

-

-

-

233,717

Cost of employees stock ownership plan (ESOP)

-

-

-

-

-

-

-

-

579,653

579,653

Β Balance at 30 September 2022

29,825,134

3,963,946

27,096,858

1,549,445

18,947

(12,259,981)

11,981

12,573,600

1,751,123

64,531,053

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Sep. 30, 2023

Issued and paid up capital

Legal reserve

General reserve

General risk reserve

Capital reserve

Reserve for financial assets at fair value through OCI

Banking risks reserve

Retained earnings

Reserve for employee stock ownership plan

Total

Β 

Β 

Β 

Β 

Β 

Beginning Balance at 1 Januray 2023

29,825,134

3,963,946

27,096,858

1,549,445

18,947

(13,138,461)

11,981

16,497,346

1,895,435

67,720,631

Capital increase

369,876

-

-

-

-

-

-

-

-

369,876

Transferred to reserves

-

806,408

12,743,849

-

2,208

-

-

(12,388,223)

(1,164,242)

-

Dividend paid

-

-

-

-

-

-

-

(3,738,888)

-

(3,738,888)

Net profit for the period

-

-

-

-

-

-

-

21,732,076

-

21,732,076

Transferred to RE from financial assets at fair value through OCI

-

-

-

-

-

(95,308)

-

95,308

-

-

Net unrealised gain/(loss) on financial assets at fair value through OCI after tax

-

-

-

-

-

(9,611,703)

-

-

-

(9,611,703)

Transferred (from) to banking risk reserve

-

-

-

-

-

-

3,249

(3,249)

-

-

Effect of ECL in fair value of debt instruments measured at fair value through OCI

-

-

-

-

-

197,888

-

-

-

197,888

Cost of employees stock ownership plan (ESOP)

-

-

-

-

-

-

-

-

608,250

608,250

Β Balance at 30 September 2023

30,195,010

4,770,354

39,840,707

1,549,445

21,155

(22,647,584)

15,230

22,194,370

1,339,443

77,278,130

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
QRTUPGMPGUPWGRP
Date   Source Headline
12th May 202610:18 amRNS1st Quarter Results
12th May 202610:16 amRNSCIB Consolidated Financial Statements 1Q26
12th May 202610:15 amRNS1Q26 Earnings Release
16th Mar 20267:00 amRNSResolutions Ordinary General Assembly March 2026
16th Mar 20267:00 amRNSResolutions Extraordinary GA March 2026
16th Mar 20267:00 amRNSResolutions Ordinary General Assembly March 2026
16th Mar 20267:00 amRNSResolutions Extraordinary GA March 2026
24th Feb 202612:31 pmRNSItems of Extraordinary GA
24th Feb 20267:00 amRNSPress Release dated 23th February 2026
19th Feb 20261:20 pmRNSItems of Extraordinary GA
19th Feb 20261:17 pmRNSInvitation to the Extraordinary GA 2026
19th Feb 20268:00 amRNSItems of OGA 2026
19th Feb 20268:00 amRNSInvitation to the OGA March 15
10th Feb 20267:00 amRNSCIB Summary of Board Resolution 9 Feb 2026
10th Feb 20267:00 amRNSFY25 Earnings Release
10th Feb 20267:00 amRNSCIB IFRS Consolidated Financial Statements FY25
15th Dec 20257:00 amRNSChange in Board of Directors
3rd Dec 20254:35 pmRNSCIB Bonus Shares Distribution 2025
4th Nov 20257:00 amRNSCIB Condensed Consolidated 3rd Quarter Results
4th Nov 20257:00 amRNSCIB 9M25 Earnings Release
4th Nov 20257:00 amRNS3rd Quarter Results
25th Sep 20253:55 pmRNSSummary of Resolutions - GAM September 2025
1st Sep 20257:02 amRNSInvitation to General Assembly September 2025
22nd Jul 20257:00 amRNSCIB 1H2025 Condensed Consolidated Financials
22nd Jul 20257:00 amRNSCIB 1H2025 Condensed Separate Financials
22nd Jul 20257:00 amRNS2Q25 Earnings Release
28th May 20256:00 pmRNSChanges to the Board of Directors
13th May 20257:00 amRNSSeparate- Q12025
13th May 20257:00 amRNS1Q25 Press Release
13th May 20257:00 amRNSConsolidated Financial Position at March 31.2025
24th Mar 20257:00 amRNSOrdinary General Assembly Resolutions Summary 2025
28th Feb 20257:00 amRNSGeneral Assembly 2025 - Discussion Items - amended
27th Feb 20257:47 amRNSInvitation to General Assembly 2025
27th Feb 20257:15 amRNSGeneral Assembly 2025 - Discussion Items
19th Feb 20257:00 amRNSCIB Annual Financial Report
19th Feb 20257:00 amRNSCIB FY2024 Earnings Release
6th Nov 20247:58 amRNSCIB gets regulatory approvals to changes to BoD
4th Nov 20247:00 amRNSEarnings Release 3Q.2024
4th Nov 20247:00 amRNSCIB-Separate Financial Statements 3Q.2024
4th Nov 20247:00 amRNSCIB-Consolidated Financial Statements 3Q.2024
1st Oct 20242:00 pmRNSCIB obtaining Long term loan from IFC
16th Sep 20248:00 amRNSChanges in CIB's Board of Directors
22nd Jul 20247:00 amRNSH1.2024 Press Release
22nd Jul 20247:00 amRNSCIB H1-2024 Separate Financial Statements - E
22nd Jul 20247:00 amRNSCIB H1-2024 Consolidated Financial Statements
13th May 20247:00 amRNS1st Quarter Results - Consolidated Statements
13th May 20247:00 amRNS1st Quarter Results - Separate Statements
26th Mar 20247:49 amRNSChanges in CIB's BOD - 25 March 2024
26th Mar 20247:00 amRNSEGM Resolutions - March 25th, 2024
26th Mar 20247:00 amRNSOGM Resolutions - March 25th, 2024

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.